What are the key takeaways for Tempus AI Inc ($TEM)?

Tempus AI achieved a significant milestone in Q2 2026, posting net income of $5.6 million (EPS $0.03), a positive inflection from previous quarterly losses. Revenue growth remains robust, increasing 21.6% YoY to $382.5 million, reflecting steady demand for the company’s genomic testing and data services. Stock-based compensation remains elevated at $54.1 million for the quarter, highlighting continued heavy reliance on equity-based incentives for talent acquisition.

Tempus AI Inc (TEM) AI Stock Analysis: Earnings, Risks & Summary

Please enable JavaScript to continue using this application.

Latest Report Overview for Tempus AI Inc ($TEM)

AI-powered analysis of Tempus AI Inc (TEM) stock based on Q2 2026 financial data.

Published: September 7, 2026

Latest Report Overview

Tempus AI Inc (TEM) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $382 million with diluted EPS of $0.03 and net income of $6 million. Operating margin was -19.8%, and free cash flow was $-19 million for the period. Management continues to focus on scaling the data platform and expanding diagnostic testing volumes. The company's strategy involves integrating AI tools into clinical workflows to drive adoption and generate recurring data streams. Growth in the genomic testing business remains a primary revenue engine, supplemented by high-margin data licensing and clinical trial matching services. Liquidity remains a key area of focus as the company manages significant operational expenses, including substantial stock-based compensation, which reached $54.1 million in Q2 2026. Despite the net income, free cash flow remained negative, indicating that the business requires continued investment in lab infrastructure and AI talent to maintain its competitive position in the precision medicine market.

Key Takeaways for Tempus AI Inc

Tempus AI achieved a significant milestone in Q2 2026, posting net income of $5.6 million (EPS $0.03), a positive inflection from previous quarterly losses.
Revenue growth remains robust, increasing 21.6% YoY to $382.5 million, reflecting steady demand for the company’s genomic testing and data services.
Stock-based compensation remains elevated at $54.1 million for the quarter, highlighting continued heavy reliance on equity-based incentives for talent acquisition.
Operating cash flow was negative ($7.5 million), indicating that while the business is scaling revenue, it still requires external capital or operational optimization to reach cash-flow neutrality.
The company's gross margin was 64.4%, demonstrating strong pricing power and product efficiency in its diagnostic and data segments.
Data flywheel initiatives continue to be the core long-term strategic focus, with management emphasizing the value of their growing library of clinical and molecular data.

What Does Tempus AI Inc Do?

Tempus AI Inc is a technology company focused on precision medicine, leveraging a massive proprietary library of clinical and molecular data to drive insights. The company serves a diverse set of healthcare stakeholders, including biopharmaceutical companies, research institutions, and healthcare providers, by providing diagnostic testing and AI-driven clinical insights. Its core offerings include genomic and molecular diagnostic tests, a sophisticated data analysis platform that integrates clinical and real-world data, and tools for clinical trial matching. The company operates at the intersection of healthcare and technology, positioning itself as a foundational platform for 'data-driven' healthcare decisions, with extensive scale indicators such as a broad network of diagnostic laboratory operations and strategic partnerships with major health systems.

Growth Drivers for Tempus AI Inc

Scaling genomic and molecular diagnostic testing volumes across existing and new clinical provider networks.
Expansion of data licensing partnerships with biopharma customers for clinical trial design and drug discovery.
Increased adoption of AI-enabled 'Tempus One' and other decision-support tools by health systems.
Strategic R&D investment to enhance the precision and accuracy of predictive algorithms.
Expansion into new oncology and non-oncology therapeutic areas to widen the target market.

Overview Charts AI Summary Financials Valuation

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Tempus AI, Inc. ($TEM)

Key Takeaways

1.Tempus AI achieved a significant milestone in Q2 2026, posting net income of $5.6 million (EPS $0.03), a positive inflection from previous quarterly losses.
2.Revenue growth remains robust, increasing 21.6% YoY to $382.5 million, reflecting steady demand for the company’s genomic testing and data services.
3.Stock-based compensation remains elevated at $54.1 million for the quarter, highlighting continued heavy reliance on equity-based incentives for talent acquisition.
4.Operating cash flow was negative ($7.5 million), indicating that while the business is scaling revenue, it still requires external capital or operational optimization to reach cash-flow neutrality.
5.The company's gross margin was 64.4%, demonstrating strong pricing power and product efficiency in its diagnostic and data segments.
6.Data flywheel initiatives continue to be the core long-term strategic focus, with management emphasizing the value of their growing library of clinical and molecular data.

What They Do

How They Make Money

Tempus AI’s revenue model is anchored in the delivery of diagnostic services and the licensing of insights derived from its data platform. A significant portion of revenue is generated through clinical testing services, which are recognized at the point of test delivery. The company also generates recurring revenue through long-term data licensing agreements with biopharmaceutical companies and subscription-like relationships with health systems that utilize its AI-powered insights tools. Growth is primarily driven by expanding the volume of genomic tests processed, increasing the number of clinical sites where its diagnostic and software products are deployed, and improving the 'attach rate' of data services to its diagnostic core. The combination of high-margin data insights with the diagnostic business provides a synergistic economic engine, where the diagnostic reach expands the data, and the data increases the value of the software offering.

Competitive Position

Tempus AI competes primarily with established diagnostic testing firms, such as Foundation Medicine and Guardant Health, as well as electronic medical record (EMR) companies that are increasingly developing their own analytic layers. Its primary competitive advantage lies in the integration of its own high-volume, proprietary laboratory testing with a deep, multimodal data layer that includes clinical, genomic, and imaging data. Relative to peers, Tempus AI exhibits higher growth rates, though its valuation is often weighed against its history of cash burn and reliance on high-cost scientific and engineering talent. While its position is strong due to the proprietary nature of its data flywheel, it faces constant pricing and reimbursement pressure from payers (insurance) and competition from larger tech incumbents seeking to move into healthcare data and AI analytics.

Business Strategy & Moat

Tempus AI's strategy centers on a 'data flywheel' mechanic: provide high-value diagnostic tests to clinicians, collect resulting data, enrich that data using AI, and sell the resulting insights back to biopharma and research entities. This creates a durable advantage: the more clinical data it collects, the more valuable its AI models become, and the more valuable its offerings become to biopharma customers. Capital allocation is heavily skewed toward R&D and lab infrastructure, with a disciplined focus on maintaining gross margins while scaling volume. Switching costs are moderate to high, as clinical sites integrate Tempus’s tools into their decision-making workflows, making it difficult for competitors to replace them once embedded. The strategy is currently focused on achieving durable, profitable growth rather than just top-line expansion, as evidenced by recent net income improvements.

Industry Outlook

The precision medicine and health tech industry is characterized by rapid innovation and increasing integration of AI, though it remains constrained by regulatory hurdles, specifically regarding data privacy and the clinical validation of AI models. Near-term tailwinds include the rising importance of targeted therapies and the shift toward value-based care, which rewards companies that can provide better clinical outcomes through data. Regulatory environments in the U.S. and abroad are becoming more stringent regarding the training and deployment of AI in medical settings. While this acts as a barrier to entry, it also increases compliance costs for incumbents. The overall market is in a growth phase, with demand for actionable data insights expected to accelerate as biopharma firms seek to reduce drug development costs and increase trial efficiency.

Growth Drivers

•Scaling genomic and molecular diagnostic testing volumes across existing and new clinical provider networks.
•Expansion of data licensing partnerships with biopharma customers for clinical trial design and drug discovery.
•Increased adoption of AI-enabled 'Tempus One' and other decision-support tools by health systems.
•Strategic R&D investment to enhance the precision and accuracy of predictive algorithms.
•Expansion into new oncology and non-oncology therapeutic areas to widen the target market.

Recent Developments

•Achieved first positive net income quarter in Q2 2026, signaling a shift toward operational efficiency.
•Continued scaling of diagnostic lab capacity to support 21.6% YoY revenue growth.
•Ongoing investment in AI research and development, maintaining quarterly R&D spend above $50M.
•Successful retention and expansion of key biopharma data licensing contracts.

Catalysts

•Upcoming regulatory decisions regarding new diagnostic tests (LDTs) could expand the addressable market.
•Potential announcements of new major biopharma data licensing partnerships in Q3/Q4.
•Quarterly earnings reports demonstrating consistent net income profitability will be a key signal for the market.
•Launch or scale-up of new AI diagnostic tools in non-oncology clinical areas.
•Macro trends impacting clinical trial budgets could accelerate or delay data licensing revenue.

RPO & Key Performance Indicators

•Revenue grew 21.6% YoY in Q2 2026, demonstrating persistent demand for services despite industry-wide cost pressures.
•Gross margin of 64.4% suggests efficient scaling and pricing power in diagnostic offerings.

Strengths

•Proprietary multimodal data library serves as a durable, difficult-to-replicate competitive advantage.
•Strong revenue growth momentum with 21.6% YoY increase in the most recent quarter.
•Successful shift to profitability in Q2 2026, showing discipline in managing operating costs.
•Integrated platform strategy (diagnostics + data) creates synergistic revenue streams and switching costs.
•High gross margins relative to standard clinical labs, indicating a premium product and strong market positioning.

AI Benefits & Opportunities

•AI-powered predictive modeling enhances the value of proprietary datasets, allowing for premium pricing in clinical trial matching and biopharma licensing.
•Operational efficiencies from automating genomic data processing speed up time-to-result for clinicians, improving customer retention.

Risks & Concerns for Tempus AI, Inc. ($TEM)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Tempus AI, Inc. (TEM, filings period ending June 30, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Sep 7, 2026.

Peers of Tempus AI, Inc. (TEM)